Dr. Drejer has more than 20 years of experience in the pharmaceutical industry. Before joining Symphogen, she held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. In addition to her service on Symphogen’s board of directors, Dr. Drejer is also a member of the board of directors of Danisco A/S and Bioneer A/S. Her scientific experience includes research and development of drugs for the treatment of Diabetes and she was instrumental in the Insulin Analogue and Nasal Insulin programs of Novo Nordisk.
